England Sees Past Price Tag To Back GSK Bubble Baby Gene Therapy

 
• By Kevin Grogan

The cost of Strimvelis for treating severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is €594,000 but NICE has confirmed that it thinks the benefits of GSK's gene therapy, administered at a hospital in Milan, represents a fair price.

Bubbles
NICE backs GSK's bubble baby syndrome drug • Source: Shutterstock

More from Drug Pricing

More from Scrip